A key step in the progression of breast cancer is the conversion of cells from an estrogen-dependent to an estrogen-independent state. Yet the molecular mechanisms underlying this transition in the control of cell proliferation of breast cancer cells remain poorly understood. A potential role for Ras-related GTPases in this process was suggested by the finding that BCAR3/AND-34, a protein isolated on the basis of its ability to convert MCF-7 and ZR-75 breast cancer cell lines to estrogen independence and tamoxifen resistance, is a guanine nucleotide exchange factor with the potential to activate the Ras-related Ral, R-Ras and Rap GTPases. In this study we investigated the potential contribution of these GTPases to the generation of estrogen-independence in MCF-7 cells. We found that elevated R-Ras but not Ral or Rap activity was sufficient to induce estrogen-independent proliferation of MCF-7 cells. The effect of R-Ras was dependent upon its ability to constitutively activate the AKT kinase. Interestingly, although AKT was also constitutively activated when estrogen-independent proliferation was induced by overexpression of EGF receptors, this mechanism of hormone independence did not require AKT activation. In contrast, EGF receptors did require Ral activation to induce estrogen-independent proliferation, while Ral activation was not required for estrogen-induced proliferation of MCF-7 cells. These findings suggest that Ral activity takes on a significant role in controlling cell proliferation of breast cancer cells when progression to estrogen-independence is associated with over-expression of EGF receptor family members. Moreover, because RRas promotes hormone-independent growth in a manner distinct from EGF receptors, it may participate in the conversion of breast cancer cells to estrogen independence when over-expression of EGF receptor family members is not involved.
Introduction
Most breast cancers originally contain cells that express receptors for estrogen, and in these cases 17b-estradiol (E2) has potent mitogenic effects (Scott and McGuire, 1991) . As such, E2 antagonists such as tamoxifen block the proliferation of cells from this class of tumor and represent an effective anti-cancer treatment, albeit temporarily. This is because most breast tumors inevitably become estrogen independent and develop resistance to tamoxifen. The mechanisms underlying this transition and how cell proliferation is regulated once estrogen independence is achieved are research areas under intense scrutiny (reviewed in Wiebe et al., 1993) .
In many cases estrogen independent and tamoxifenresistant tumors display elevated expression of EGFR family members, such as HER2, which are thought to contribute to the oncogenic phenotype of the tumor cells (Riese and Stern, 1998) . The significance of this phenomenon is highlighted by the fact that HER2 has become a drug target in clinical use for this class of estrogen-independent tumors (Wang et al., 2001 ). Moreover, forced over-expression of EGFR family members is sufficient to support hormone-independent proliferation in estrogen-dependent breast cancer cell lines (Liu et al., 1995; Pietras et al., 1995; van Agthoven et al., 1992) . EGFR family members function by activating a variety of downstream signaling cascades including those initiated by the Ras GTPase. In fact, expression of constitutively activated versions of Ras (Kasid et al., 1985) or one of its downstream targets, Raf (El-Ashry et al., 1997; Oh et al., 2001) , in these breast cancer cell lines also promotes hormone independent growth.
Ras can bind to and activate additional target proteins that may also participate in EGFR mediated proliferation of breast cancer cells (Takai et al., 2001) . For example, active GTP-Ras binds to PI3-kinase, a lipid kinase that produces the second messengers, PIP2 and PIP3. PI-3 kinase activity (Salh et al., 2002) or the activity of downstream kinases dependent upon its activity, such as AKT (Bellacosa et al., 1995; Nakatani et al., 1999) , has been frequently found to be elevated in estrogen-independent tumors. Moreover, expression of activated PI3-kinase or AKT, a protein kinase whose activity is regulated by PIP-3, can partially support hormone-independent growth, possibly through activation of E2 receptors (Campbell et al., 2001) .
A third Ras target that may contribute to the transition to hormone independence is a family of guanine nucleotide exchange factors (GEFs) that promote the active GTP bound state of the Ras-related Ral GTPases, RalA and RalB. Ral-GTPases function in both the regulation of vesicle sorting and cell proliferation. A role in vesicle sorting was first suggested by the finding that a large fraction of Ral exists in endocytic and exocytic vesicles (Bielinski et al., 1993) . Subsequently, Ras was shown to influence endocytosis through its downstream target RalBP1 (Nakashima et al., 1999) and exocytosis and polarized secretion through its other downstream target, the exocyst complex (Brymora, 2001 Polzin, 2002 Moskalenko, 2002 Brymora, 2001 . Ral also promotes cell proliferation in most cell types studied to date and can complement transformation induced by other Ras effectors such as Raf and PI3 kinase (Wolthuis et al., 1997) . Although the precise target protein involved has not been identified, c-Src may be involved since elevated Ral activity has been shown to mediate activation of cSrc and Stat3 induced by EGF receptors (Goi et al., 2000) . The fact that elevated levels of EGF receptor family members and enhanced activity of Src (Biscardi et al., 1999) and Stat3 (Turkson and Jove, 2000) have routinely been observed in breast cancer samples first suggested a possible link between Ral signaling and the breast cancer development. This suggestion was reinforced by the finding that BCAR3/AND-34, a protein identified on the basis of its ability to promote estrogen and tamoxifen resistant proliferation of breast cancer cell lines (van Agthoven et al., 1998) was found to be a putative Ral-GEF (Gotoh et al., 2000) .
BCAR3/AND34 was also found to be a potential GEF for Ras related R-Ras and Rap GTPases (Gotoh et al., 2000) . These GTPases are quite similar to Ras and have the ability to bind to the same target proteins (Takai et al., 2001 ). Yet for reasons that are not understood, their function in cells is much more restricted, such that Rap only activates one form of Raf, B-Raf (Ohtsuka et al., 1996) while it does not consistently activate Ral-GEFs or PI3-kinase. In contrast, R-Ras activates PI3-kinase (Marte et al., 1997) but not Raf or Ral-GEFs. Interestingly, both of these Ras-related proteins also promote a function not associated with Ras, inside/out integrin activation (Bos et al., 2001; Caron et al., 2000; Keely et al., 1999; Zou et al., 1999) .
In this study, we investigate the possible role of these Ras-related GTPases in the conversion of estrogendependent breast cancer cells to estrogen independence. We found that expression of a constitutively activated R-Ras was sufficient to induce estrogen independent proliferation of MCF-7 cells. While constitutively elevated Ral activity was not sufficient, Ral activation was required for over-expressed EGF receptors to promote hormone independent proliferation. Furthermore, we found that EGF receptors and R-Ras appear to promote estrogen independent proliferation through a different set of signaling pathways, suggesting that they may participate in different mechanisms of breast cancer cell progression.
Results
Over-expression of either BCAR-3/AND-34 or EGFR promotes estrogen independent growth of MCF-7 cells It has been demonstrated that over-expression of either BCAR-3/AND-34 (van Agthoven et al., 1998) or EGF receptors (EGFR) (van Agthoven et al., 1992) promotes estrogen-independent growth in breast cancer cell lines. However, the mechanisms involved are not well understood. We have shown that overexpressed of BCAR-3/AND-34 in 293 cells has the capacity to function as a guanine nucleotide exchange factor for co-transfected Ral, R-Ras and Rap1 GTPases (Gotoh et al., 2000) . Thus, to begin to assess the contribution of these Ras related GTPases in the conversion of breast cancer cells to estrogen independent growth, we first attempted to confirm that overexpression of BCAR-3/AND-34 or EGFR can promote estrogenindependent growth in MCF-7 cells.
Vectors expressing Myc-tagged BCAR3/AND-34 or EGFR were transfected into MCF-7 breast cancer cells. Multiple clones containing BCAR-3/AND-34, EGFR or empty vector were selected. Growth assays were performed starting with 2610 4 cells in either complete medium or medium lacking estrogen (E2). The estrogen antagonist ICI 182,780 was also included to eliminate any growth promoting effects that may function through non-ligand dependent activation of estrogen receptors in cells. For EGFR over-expressing cells, 5 ng/ml EGF was also added. Medium was changed every 48 h and then cells were counted at various times. Control cells increased their cell number by only about sevenfold after 15 days in culture in the absence of E2 stimulation. In contrast, under these same conditions, BCAR3/AND-34 expressing cells increased their cell number *50-fold over the same time period (Figure 1a ). For comparison, both control and BCAR-3/AND-34 expression cells increased their cell number 200-fold when grown in complete medium (Figure 1b) , containing estrogen. Similar results were obtained with cells over-expressing EGFR (Figure 1c ). These results confirmed earlier studies and allowed us to investigate the underlying mechanisms.
EGFR but not BCAR-3/AND-34 induces Ral-GTP levels in MCF-7 cells
To determine whether EGFR or BCAR-3/AND-34 promotes estrogen-independent proliferation through activation of the Ral GTPase, the amount of active GTP-RalA present in these various MCF-7 cell lines was assayed using a fusion protein of GST and the Ral binding-domain of the Ral target RalBP (GST-RBD) as an affinity reagent (Figure 2a) . To compare control cells to cells over-expressing EGFR, cells were first serum starved and then stimulated with EGF (5 ng/ml) for various amounts of time and then cell lysates were assayed for active GTP-RalA content. EGF treatment of control cells (pcDNA3), which are known to have very low levels of EGFR, did not significantly raise Ral-GTP levels. As expected, in cells over-expressing EGFR, EGF treatment increased the amount of active Ral (*threefold) within 1 min, which then returned to baseline within 30 min. Similar results were obtained for RalB (data not shown). The ability of these cells to respond to EGF was assessed independently by assaying for the presence of tyrosine phosphorylated EGFR and activation of ERK. As expected, control MCF-7 cells yielded barely detectable phosphorylation of EGFR and low levels of ERK activation. In contrast, cells over-expressing EGFR displayed strong signals for both tyrosine phosphorylated EGFR and activated ERK. These findings suggest that overexpression of EGFR could potentially promote estrogen independent growth through activation of the Ral GTPase. figure) . 2610 4 cells were plated in E2 free medium (a) containing 100 nM ICI182,780 or (b) E2-containing medium. Cell number was counted after 0, 5, 10 and 15 days. (c) Cells were stably transfected with either EGFR or pcDNA3. Growth assays were performed as described above except that 5 ng/ml of EGF was added and only the data on day 15 is shown. The results for growth assay represent the mean+s.d. from triplicate experiment of representative clones An analogous set of experiments was performed on cells over-expressing BCAR-3/AND-34. In this case, control cells were compared to BCAR-3/AND-34 expressing cells under the same conditions used for growth assays. No difference in RalA-GTP levels ( Figure 2b ) or RalB-GTP levels, (data not shown) between the two cell types was observed, suggesting that Ral activation was not responsible for BCAR-3/ AND-34 induction of estrogen-independent cell proliferation. Possibly, BCAR-3/AND-34 is a relatively weak Ral-GEF and levels expressed in these cells that were capable of promoting cell proliferation were not sufficient to activate RalA. Alternatively, BCAR-3/AND-34 cannot activate Ral in this cellular context.
Ral-GTPase activity is necessary for estrogen independent cell proliferation induced by EGFR
To test whether Ral activity contributes to EGFRinduced estrogen independent growth, we assayed the consequence of inhibiting Ral activation on EGFR function in MCF-7 cells. A vector expressing dominant negative Ral, RalA28N, or control vector were stably transfected into a representative EGFRoverexpressing MCF-7 cell line. Multiple clones expressing dnRal28 and control vector, were expanded and cell proliferation assays were performed as described above (Figure 3a ). Ral28N expression significantly reduced cell proliferation in the absence of estrogen compared to control cells expressing EGFR and empty expression vector. In contrast, no difference was observed when cells were grown in complete medium.
To begin to determine how Ral28N suppressed EGFR effects on cell proliferation in MCF-7 cells, we first confirmed that it blocked EGF activation of Ral. EGF was used to stimulate control EGFR-overexpressing cells and EGFR-overexpressing cells co-expressing Ral28N. The level of the active form of RalA was assessed as described previously, and as expected both were reduced in two individual clones expressing Ral28N in both basal conditions, and after EGF treatment (Figure 3b) . Importantly, the specificity of Ral28N expression was confirmed by the finding that tyrosine phosphorylation of EGFR and the activation of both MAPK and AKT were indistinguishable in control and Ral28N expressing MCF-7 cells ( Figure  3c ).
Previously, we demonstrated that EGFR promotes c-Src and Stat3 activation through activation of Ral (Goi et al., 2000) . To test whether this feature of EGFR function was suppressed in cells whose Ral signaling pathway was blocked, EGFR activation of a Stat3 responsive reporter was assessed. EGFR expressing cells and their Ral28N-expressing counterparts were cultured in E2-free medium for 2 days and then transiently transfected with an SIE-luciferase plasmid and a plasmid containing a minimal promoter-renilla construct as a control. After 24 h, cells were stimulated with either EGF (5 ng/ml) or buffer for 24 h. Figure 3d shows that Ral-28N expression suppressed the Stat3 reporter activation by EGF, suggesting that Ral-mediated Stat3 activation may contribute to estrogen-independent growth induced by EGFR in MCF-7 cells.
Ral activity has been shown to contribute to cyclin D1 protein elevation upon growth factor stimulation through activation of NF-kB (Henry et al., 2000) . To determine whether dnRal28N may suppress EGF induction of cell cycle via a suppression of cyclin D1, cells were grown in E2-free medium for 2 days, serum-starved for 12 h and stimulated with EGF (5 ng/ml) for various times. As predicted from previous studies, immunoblotting for cyclin D1 in representative cell lines showed that EGF treatment caused an elevation of cyclin D1 levels for 24 h in control cells but not in cells expressing Ral28N (Figure 3e ).
Ral activity is not necessary for cell proliferation of breast cancer cells induced by estrogen
Experiments described above showed that expression of dnRal28N in EGFR over-expressing MCF-7 cells had no effect on cell proliferation when the cells were grown in complete medium containing estrogen. To confirm that suppressing Ral activity has no detectable effect on the ability of estrogen to promote cell proliferation in estrogen dependent cells, Ral28N was Figure 2 Over-expression of EGFR but not BCAR-3/AND-34 activates Ral proteins. (a) A representative clone of EGFR cells was cultured in E2-free medium for 2 days, serum starved for 24 h, and stimulated with 5 ng/ml EGF for various times. Lysates were analysed for Ral-GTP levels by affinity purification using a GST fusion with Ral binding domain of RalBP (GST-RalBD) immobilized on S-hexyglutathione-agarose beads. Immunoblots of GTP-Ral and total Ral were visualized with specific monoclonal antibodies against Ral A. Tyrosine phosphorylation of EGFR was detected using specific antibodies against phospho-tyrosine. Activation of MAP kinases (Erk1/2) was determined using specific antibodies against phospho-Erk1/2. (b) A representative clone of BCAR-3/AND-34 cells was cultured in E2-free medium for 2 days, serum-starved for 24 h, and Ral-GTP levels were determined as previously described Figure 3 (a) Ral28N inhibits EGFR induced estrogen-independent growth. A representative clone of EGFR over-expressing cells was stably transfected with either dominant negative Ral28N or pPcDNA. Positive clones were obtained after both hygromycin and G418 selection. Growth assays were performed in the presence of 5 ng/ml EGF as described previously. The results are presented as mean+s.d. from four clones for EGFR+pcDNA3 cells and seven clones for EGFR+Ral28N cells. Ral28N expression was detected as an increase in total RalA protein using specific monoclonal antibodies against Ral A. (b) Ral28N inhibits Ral A activation induced by EGF. Two representative clones of EGFR+Ral28N and EGFR+pcDNA3 cells were cultured in E2-free medium for 2 days, serum starved for 24 h, and stimulated with 5 ng/ml EGF for 1 min. Cell lysates were analysed for Ral A-GTP levels as described. (c) Ral28N does not suppress general EGFR function. Ral28N cells stimulated with EGF as described above were assayed for EGFR receptor phosphorylation, ERK1/2 activation and AKT activation as described previously. (d) Ral28N suppresses EGFR activation of Stat3 reporter activity. Representative clones of EGFR+Ral28N and EGFR+pcDNA3 cells were cultured in E2 free medium for 2 days and then transiently transfected with a Stat3 responsive SIE-luc reporter construct along with a basal promoterRenilla construct. After 24 h, cells were cultured in a low serum (0.5%) medium in the presence or absence of 5 ng/ml EGF for 24 h. Results are presented as relative luciferase activity (SIE-luc/Renilla-luc)+s.d. from triplicate experiments P50.05. (e) Ral28N expression blocks EGFR activation of cyclin D1 expression. A representative clone of EGFR+Ral28N or EGFR+pcDNA3 was cultured in E2-free medium for 2 days, serum-starved for 24 h and then stimulated with 5 ng/ml of EGF. Cell lysates prepared as a function of time and immunoblotted for cyclin D1 proteins using Ral A proteins were detected using specific monoclonal antibodies against Ral A. The result is a representative from at least two separate experiments stably expressed in parental MCF-7 cells. Here again, Ral28N expression had no effect on the proliferation of either cell type (Figure 4a ) in this case either in complete medium or in E2 free medium. These data show that while Ral activity is required for breast cancer cells to grow efficiently in response to EGF, it is not required for cells to grow in response to estrogen. Figure 4 Ral effects on MCF-7 cell proliferation (a) Ral28N has no effect on estrogen dependent growth. MCF-7 cells were stably transfected with either Ral28N or pcDNA3. Positive clones were obtained after G418 selection. Growth assays were performed either in E2-free medium or E2 medium. The results represent the mean+s.d. from four individual Ral28N and three pcDNA3 clones. Ral28N proteins were detected using specific monoclonal antibodies against Ral A. (b) Ral activation is not sufficient to induce hormone independent growth. Cells were transfected with either Myc-tagged RalGDSDN or pcDNA3. Positive clones were obtained after G418 selection. Growth assays were performed as described previously and cell number after 15 days is presented. The results are presented as mean+s.d. from six individual RAlGDSDN clones and three pcDNA3 clones. RalGDSDN protein expressed in a representative clone is shown. Two representative clones of RalGDSDN and pcDNA3 cells were cultured in E2-free medium for 2 days and serum-starved for 24 h. Cell lysates were used for detecting Ral-GTP level using GST-RalBD pull-down assay
Ral activity is not sufficient to induce estrogen independent proliferation of MCF-7 cells
To test whether constitutive Ral activation was sufficient to promote estrogen independent growth, cells were stably transfected with either a constitutively activated Ral-GEF or constitutively activated Ral itself. For the activated Ral-GEF, Myc-tagged RalGDS with its N-terminus deleted, DN-Ral-GDS was used (Rusanescu et al., 2001; Tian et al., 2002) . Multiple independent clones of MCF-7 over-expressing RalGDSDN showed no enhancement of proliferation over control transfected cells under E2 free conditions, even though a significant increase in RalA-GTP levels was detected (Figure 4b ). Moreover, cells overexpressing a GTPase deficient, constitutively activated Ral72L mutant also failed to show elevated growth under these conditions compared to their control transfected counterparts (data not shown). Overall these data show that activation of Ral proteins alone is necessary for EGFR to promote estrogen-independent growth of MCF-7 cells but it is not sufficient.
R-Ras38V but not Rap1A64E induced estrogenindependent growth
Because we found that BCAR-3/AND-34 does not promote estrogen-independent proliferation through Ral activation, we tested other potential targets of the GEF, including R-Ras and Rap1. MCF-7 cells were stably transfected with constitutively activated, GTPase deficient mutants of either R-Ras, R-Ras38V or Rap1, Rap1A64E. Multiple clones expressing these GTPases were selected and assayed for estrogen independent growth as described previously. Expression of activated Rap1 had no observable effect on estrogen-independent proliferation (Figure 5a ). In contrast, activated R-Ras expression was as effective as expression of either EGFR or BCAR-3/AND-34 in promoting growth in the absence of estrogen, displaying about a sevenfold increase in cell number in comparison to the control transfected cell lines ( Figure  5b ). However, expression of activated R-Ras had no effect when cells were grown in complete medium. Thus, BCAR-3/AND-34 may promote estrogen-independent growth through activation of R-Ras. Unfortunately, we could not add support for this hypothesis by assaying for R-Ras GTP levels in MCF-7 cells, since an assay comparable to that used for Ral was not sensitive enough to detect changes in the activation state of endogenous R-Ras.
Involvement of AKT in R-Ras but not EGFR-induced proliferation of MCF-7 cells
R-Ras is similar to Ras in that it has the potential to bind to the same set of effector proteins, such as Raf, Ral-GDS and PI3 kinase. However, for reasons that are not understood, in cells R-Ras can activate only PI3-kinase. We therefore tested whether R-Ras might promote cell proliferation in the absence of estrogen through PI3-kinase activation by assaying for the activation state of a downstream effector of this enzyme, AKT. Phospho-specific antibodies that recognize only the active form of AKT were used in immunoblots to show that AKT activity was in fact elevated in MCF-7 cells compared to control cells (Figure 6a ). Consistent with previous data, we found that expression of activated R-Ras did not enhance the activity of ERK kinases (Figure 6a) .
To determine whether R-Ras induced activation of AKT function is required for estrogen independent proliferation, a dominant negative of AKT mutant Figure 5 R-Ras38V but not Rap164E promotes estrogenindependent growth. Cells were stably transfected with either Rap1A63E or Myc-tagged R-Ras38V or pcDNA3. Positive clones were selected after G418 selection. Growth assays were performed as described previously. Cell number after 15 days in culture is expressed. The results are presented as the mean+s.d. Data from three individual clones was pooled for Rap1A63E experiments (a) and data from two individual clones was pooled for R-Ras38V experiments (b). Expression of each GTPase is shown below S197M (dnAKT) was stably expressed into MCF-7 cells over-expressing R-Ras38V. Cells expressing dnAKT inhibited the proliferation of R-Ras38V growing in the absence of estrogen (Figure 6b ). In Figure 6 R-Ras38V-but not EGFR-induced estrogen independent growth of breast cancer cells requires activation of AKT. (a) Cells expressing activated R-Ras displayed elevated AKT activity. Two representative clones expressing activated R-Ras38V or empty vector (pcDNA3) were cultured in E2-free medium for 2 days, serum-starved, and cell lysates were collected for detection of phospho-AKT and total AKT or phospho-Erk and total Erk. (b and c) Dominant negative AKT suppressed R-Ras but not EGFR induced hormone independence. HA-tagged kinase-dead dominant negative AKT (AKTS197M), HA-dnAKT was stably introduced into MCF-7 cells expressing either R-Ras38V (b) or EGFRs (c). dnAKT expression levels were verified using antibodies against HA tag (see bottom of b and c). (d) HA-dnAKT was transfected into parental MCF-7 cells and various clones expressing the transfected protein were isolated. Growth assays were performed as described previously. Cell number was counted and data from day 15 is presented. The results present as mean+s.d. from four individual clones for R-Ras38V+pcDNA3, seven clones for R-Ras38V+dnAKT clones, four clones for EGFR+pcDNA3 and five clones for EGFR+dnAKT contrast, blockage of AKT function by expression of dnAKT had no effect on estrogen induced proliferation in R-Ras38V or parental MCF-7 cells (Figure 6c) . Interestingly, dnAKT expression also had no effect on EGFR induced proliferation in the absence of estrogen (Figure 6d) , even though the cells expressing EGFR clearly contain elevated levels of activated AKT compared to control MCF-7 cells (see Figure 3c) . These data suggest that AKT is necessary for R-Ras promoted estrogen independent growth but is dispensable for the effect of EGFR or estrogen.
Since R-Ras function is dependent on AKT activity, we then examined whether activation of AKT alone is sufficient to promote estrogen independent growth of MCF-7 cells. Cells expressing dominant active AKT (A-AKT) did not proliferate more effectively in estrogen-free media compared to cells transfected with empty vector alone (Figure 7) . Taken together, our data indicate that AKT is required for R-Ras-induced but not EGFR-induced estrogen-independent growth, however, activation of AKT activity is not sufficient to promote this phenotype.
Discussion
It is clear that a critical step in the progression of breast cancer occurs when tumor cells no longer rely on estrogen to proliferate. After this transition, tumor cells are no longer responsive to estrogen antagonists such as tamoxifen and become more difficult to treat clinically. Thus, it is important to understand how breast cancer cells lose responsiveness to estrogen. Multiple potential mechanisms have been identified, from a modification of estrogen receptor structure to altered regulation receptor gene expression (Johnston, 1997) . It is also important to understand what growth regulatory pathways predominate once estrogen is no longer relevant in order to design new effective treatments.
In this study, we have identified potentially important and distinct roles for two members of the Ras superfamily of GTPases, R-Ras and Ral in growth control of estrogen independent tumors. For the Ral GTPase, we have shown that although excess Ral activity alone is not sufficient to induce estrogenindependent proliferation in MCF-7 cells, Ral activation is important for EGF receptors to induce estrogen-independent proliferation of these cells. This was documented by experiments showing that inhibition of Ral activation through the expression of a dominant inhibitory Ral mutant suppressed estrogenindependent proliferation of EGFR over-expressing MCF-7 cells. This is significant because many estrogeninsensitive tumors over-express growth factor receptors such as EGFR(HER1) or HER2 (Johnston, 1997) and blockade of this receptor pathway is being used as antibreast cancer therapy.
We have previously shown that Ral activation couples EGFR activation to c-Src and Stat3 activation (Goi et al., 2000) . c-Src (Biscardi et al., 1999) and Stat3 (Turkson and Jove, 2000) are frequently overactive in breast cancer, suggesting that EGFR induction of these signaling molecules via Ral may be an important mechanism by which elevated EGFR content contributes to estrogen-independent growth of many breast tumors. We have added support for this hypothesis by showing that EGF-induction of a Stat3 dependent signal cascade was suppressed in EGFR/MCF-7 cells expressing dnRal. Ral activity has also been shown to participate in elevated expression of cyclin D1 induced by growth factors (Henry et al., 2000) . Consistent with this report, we found that EGF enhancement of cyclin D1 expression was also suppressed in EGFR/dnRal expressing cells. Together, these findings suggest that Ral mediated effects on Stat3 and cyclin D1 likely contribute to EGFR promotion of estrogen independent proliferation of MCF-7 cells.
Importantly, expression of dnRal had no growth inhibitory effect on EGFR over-expressing cells or parental MCF-7 cells growing in the presence of estrogen. Although estrogen has been shown to stimulate the Ras signaling cascade (Migliaccio et al., 1996) , its ability to signal directly to the nucleus may allow it to bypass a Ral-mediated signaling cascade that is crucial during EGF-dependent proliferation. These findings suggest that Ral function takes on greater significance in the control of breast cancer cell proliferation once cells progress to estrogen-independence associated with an amplification of EGF receptor family expression. In fact, a previous study (Rosario et Figure 7 Active form of AKT cannot promote estrogen-independent growth. Cells were transfected with a constitutive active form of AKT (A-AKT). A-AKT levels were examined using antibodies against AKT. Growth assays were performed as described previously. Cell number was counted and data from cells grown for 15 days are shown. The results are presented as mean+s.d. from two individual clones for A-AKT and two for pcDNA3 cells al., 2001) has shown that dnRal expression blocks cell proliferation in CAL51 cells, a breast cancer cell line that was estrogen-independent and over-expressed EGFR from its inception (Gioanni et al., 1990) .
In a previous study, we showed that BCAR3/AND-34, a protein detected on the basis of its ability to promote estrogen-independent proliferation of MCF-7 and ZR-75 cells, has the capacity to function as a GEF for three Ras family GTPases, Ral, R-Ras and Rap (Gotoh et al., 2000) . When we assayed MCF-7 cells over-expressing BCAR-3/AND-34 we failed to detect a significant increase in the level of activated Ral even though MCF-7 cells over-expressing another Ral-GEF, Ral-GDS, did. This indicated that BCAR-3/AND-34 does not function even in part through Ral activation. It is not clear why BCAR-3/AND-34 expression did not lead to constitutive Ral activation, however, it is possible that BCAR-3/AND-34 is a relatively weak Ral-GEF and that the level of BCAR-3/AND-34 sufficient to induce estrogen independent proliferation was not sufficient to activate Ral significantly.
This finding led us to investigate the role of other potential targets of BCAR-3/AND-34, and we found the striking result that expression of constitutively active R-Ras was as effective as EGFRs or BCAR-3/ AND-34 in promoting estrogen-independent proliferation. In contrast, activated Rap had no effect. R-Ras is a close relative of Ras, although among the three wellcharacterized Ras effectors, Raf, Ral-GDS and PI3 kinase, R-Ras activates only PI-3 kinase (Marte et al., 1997) . Here we generated data supporting the involvement of PI3-kinase in R-Ras mediated conversion of MCF-7 cells. First, as expected, MCF-7 cells expressing activated R-Ras displayed elevated activity of AKT, a downstream effector of PI3-kinase. Furthermore, expression of a dominant negative form of AKT suppressed R-Ras's ability to induce proliferation of MCF-7 cells grown in the estrogen inhibitor ICI182.780. Thus, AKT activation was necessary for R-Ras to support estrogen-independent proliferation. However, elevated AKT activity was not sufficient to express this function. In a previous study, overexpression of activated AKT has been found to modestly enhance proliferation of MCF-7 cells grown in ICI182,780 (Campbell et al., 2001) . The reason for this difference is not clear. Nevertheless, our findings suggest that AKT is not sufficient to produce estrogenindependent proliferation to a level comparable to that which is observed when activated R-Ras is expressed. Therefore, these findings show that another R-Ras function is required to cooperate with PI3-K/AKT activation. For example, a different PI3-K target may be involved R-Ras is also known to promote inside/out integrin activation (Keely et al., 1999; Zou et al., 1999) . In fact, this aspect of R-Ras function is thought to contribute to its ability to enhance migration and invasion of the breast cancer cell line, T47D (Keely et al., 1999) . Activated Rap1 also promotes inside/out integrin activation (Bos et al., 2001; Caron et al., 2000) , yet it was not capable of promoting hormoneindependent proliferation. This failure might be explained by the fact that unlike R-Ras, Rap1 does not activate AKT.
Remarkably, we found that although cells overexpressing EGFR also contain elevated AKT activity, this aspect of EGFR signaling was not required for estrogen independent proliferation, since cells expressing dnAKT grew just as well as control cells in the absence of estrogen. A possible explanation for this result is that EGFRs also activates the Ras/Raf/Erk signaling cascade, which has also been shown to promote estrogen-independent proliferation of MCF-7 cells (El-Ashry et al., 1997; Oh et al., 2001) . These results highlight a distinct difference between the way EGFRs and R-Ras promote breast cancer proliferation in the absence of estrogen (see Figure 8) . EGFRs depend upon a combination of signaling pathways including the Raf/ERK and the Ral-GDS/Ral cascades but not the PI3K/AKT pathway. In contrast, R-Ras uses a combination of the PI3K/AKT pathway and undefined additional pathways that may include integrin activation, but not the Raf/ERK pathway. In the end, these pathways may all converge in the nucleus to regulate a similar or a related set of genes modulated by estrogen to promote cell proliferation. Finally, since R-Ras appears to promote proliferation by a unique mechanism, perhaps alterations in R-Ras signaling participate in promoting hormone independent proliferation in cases of breast cancer where overexpression of EGFR family members does not occur.
Materials and methods

Cell culture and growth assay
Human mammary cancer-derived MCF-7 cells were maintained in MEM alpha medium supplemented with 10% Fetal Calf Serum (Hyclone). Growth assay in estrogen-free medium Figure 8 EGFR and R-Ras promote estrogen-independent proliferation by different mechanisms. While EGFRs activate the Ral-GDS/Ral, Raf, and PI3K/AKT signaling cascades, only Ral-GDS and Raf pathways are required for the generation of estrogen-independent proliferation in MCF-7 cells. In contrast, RRas induction of estrogen-independent proliferation of MCF-7 cells is not associated with activation of the Raf kinase signaling cascade and requires activation of the PI3K/AKT pathway and most likely additional undefined signaling pathways as well
